Antihypertensive effect and safety of imidapril on the patient with essential hypertension.
10.12701/yujm.1999.16.1.69
- Author:
Gue Ru HONG
1
;
Jun Ho BAE
;
Dae Jin JUN
;
Jong Seon PARK
;
Dong Gu SHIN
;
Young Jo KIM
;
Bong Sup SIM
Author Information
1. Department of Internal Medicine Yeungnam University, College of Medicine Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Imidapril;
ACE inhibitor;
Cough
- MeSH:
Angiotensin-Converting Enzyme Inhibitors;
Blood Pressure;
Cough;
Heart Failure;
Humans;
Hypertension*;
Incidence
- From:Yeungnam University Journal of Medicine
1999;16(1):69-75
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Imidapril(Tanatril(R)), a newly developed ACE inhibitor, has been used to treat hypertension and congestive heart failure. This study was designed to assess the antihypertensive effect and safety of Imidapril(Tanatril(R)) in patient with essential hypertension. 5-10mg of imidapril(Tanatril(R)) was administered once day in 30 patients with essential hypertension and followed up to 8 weeks. We tested the drug's effectiveness, safety, and the incidence of imidapril induced dry coughs. After 8 weeks of treatment with Imidapril, 76.2%(16/21) of patient showed lowered blood pressure and 47.6% showed normal blood pressure. The overall incidence of adverse effects was 33.3%(7/21). and among these adverse effects. dry cough was shown in only 9.5%. Thus, concluded that imidapril(Tanatril(R)) is as safe and effective as other ACE inhibitors. especially with imidapril showing very little incidence of dry cough compared to other ACE inhibitors.
